(19)
(11) EP 2 494 037 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.03.2015 Bulletin 2015/12

(45) Mention of the grant of the patent:
11.02.2015 Bulletin 2015/07

(21) Application number: 10773585.4

(22) Date of filing: 29.10.2010
(51) International Patent Classification (IPC): 
C12N 5/0781(2010.01)
C07K 16/00(2006.01)
C12N 15/62(2006.01)
 C07K 14/705(2006.01)
C07K 16/46(2006.01)
(86) International application number:
PCT/EP2010/006633
(87) International publication number:
WO 2011/050985 (05.05.2011 Gazette 2011/18)

(54)

CLONAL EXPANSION OF B CELLS

Klonale Expansion von B-Zellen

Expansion clonique de lymphocytes B

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 30.10.2009 EP 09013690

(43) Date of publication of application:
05.09.2012 Bulletin 2012/36

(73) Proprietors:
  • BioNTech AG
    55131 Mainz (DE)
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    55131 Mainz (DE)

(72) Inventors:
  • SAHIN, Ugur
    55116 Mainz (DE)
  • TÜRECI, Özlem
    55116 Mainz (DE)
  • SEPPMANN, Torsten
    55116 Mainz (DE)
  • HOFF, Holger
    55122 Mainz (DE)
  • SCHUMACHER, Jens
    69120 Heidelberg (DE)

(74) Representative: Schnappauf, Georg et al
ZSP Patentanwälte Partnerschaftsgesellschaft Radlkoferstrasse 2
81373 München
81373 München (DE)


(56) References cited: : 
EP-A- 0 434 879
   
  • HANKS B A ET AL: "Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/NM1183, vol. 11, no. 2, 23 January 2005 (2005-01-23), pages 130-137, XP002399130, ISSN: 1078-8956
  • LAPTEVA NATALIA ET AL: "Enhanced activation of human dendritic cells by inducible CD40 and toll-like receptor-4 Ligation", CANCER RESEARCH, vol. 67, no. 21, November 2007 (2007-11), pages 10528-10537, XP2540324, ISSN: 0008-5472
  • BANCHEREAU J ET AL: "LONG-TERM HUMAN B CELL LINES DEPENDENT ON INTERLEUKIN-4 AND ANTIBODY TO CD40", SCIENCE (WASHINGTON D C), vol. 251, no. 4989, 1991, pages 70-72, XP002576462, ISSN: 0036-8075
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).